Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index; 118 of the 220 sources its claims cite were checked for support.

Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages

Open access
Aquino, Jorge Benjamin · 2026 · Frontiers in Immunology

Abstract

Chronic liver diseases represent a major global health burden, with fibrosis as the common pathological outcome of sustained hepatic injury. Once considered irreversible, liver fibrosis is now recognized as a dynamic and potentially reversible process driven by complex cellular and molecular interactions within the hepatic microenvironment. Among these, hepatic macrophages have emerged as central regulators of both fibrogenesis and fibrosis resolution due to their remarkable phenotypic and functional plasticity. This review integrate experimental, translational, and emerging clinical evidence to propose macrophage reprogramming as a unifying therapeutic framework for liver fibrosis. A broad spectrum of intervention strategies -including gene modulation, pharmacological agents, immunometabolic reprogramming, nanotechnology-based delivery systems, and cell-based therapies- converges on promoting restorative macrophage phenotypes across toxic, metabolic, cholestatic, and inflammatory liver diseases. Particular emphasis is placed on key signaling and metabolic circuits -such as NF-κB, STAT1/3/6, PPARα/γ, AMPK, mitochondrial function, and autophagy- that collectively govern macrophage fate and function. The context-dependent nature of macrophage responses is highlighted, underscoring critical differences between toxic injury models (e.g., CCl 4 ) and chronic metabolic conditions such as MASH, where macrophage heterogeneity and immunometabolic dysregulation impose additional therapeutic challenges. Emerging clinical data indicate that many antifibrotic strategies -despite distinct primary targets- converge on shared pathways of macrophage modulation, reinforcing their role as integrative hubs linking inflammation, metabolism, and tissue repair. Collectively, current findings indicate that durable fibrosis regression is unlikely to be achieved through single-target interventions. Instead, effective therapeutic strategies will require coordinated, temporally defined modulation of macrophages alongside other hepatic cells populations. Elucidation of the hierarchy and timing of macrophage-driven repair processes will be essential for the rational design of next-generation antifibrotic interventions with improved clinical efficacy.

Overview

CoChat Summary

TL;DR

This review argues that liver fibrosis is potentially reversible and that restorative macrophages are central to fibrosis resolution through coordinated immunometabolic reprogramming, efferocytosis, and matrix remodeling. It surveys experimental and clinical evidence showing that many antifibrotic strategies converge on macrophage modulation, with the strongest translational support currently for metabolic therapies such as SGLT2 inhibitors and GLP-1 receptor agonists.

Key findings

  • Restorative macrophages are described as promoting fibrosis resolution by enhancing extracellular matrix degradation, inactivating or eliminating activated HSCs, and supporting tissue repair; they secrete IGF-I and HGF and are linked to increased MMP activity and reduced collagen deposition.
  • In mouse models, fibrosis regression is associated with macrophage phenotypes shaped by signaling and metabolic pathways including NF-κB, STATs, PPARs, AMPK, mitochondrial function, and autophagy; for example, TRPM2 activation increases phagocytosis and promotes a restorative phenotype, and SGLT2 inhibition shifts macrophage metabolism from glycolysis to oxidative phosphorylation.
  • Clinical evidence summarized in the review includes a randomized trial of pioglitazone in 55 patients, where fibrosis reduction was not statistically significant after 6 months, and later trials of metabolic therapies such as tirzepatide and semaglutide showing fibrosis benefit; semaglutide achieved at least a one-stage fibrosis improvement without worsening steatohepatitis in 36.8% vs 22.4% with placebo at week 72.
  • The review states that in a 104-week trial with 695 adults with T2DM on metformin, combined exenatide plus dapagliflozin produced greater improvements in hepatic steatosis and fibrosis markers than either agent alone.

Methods

  • Narrative review integrating experimental, translational, and clinical evidence on macrophage reprogramming in liver fibrosis across toxic, metabolic, cholestatic, and inflammatory liver diseases.
  • The paper synthesizes studies using murine models (including CCl4, MASH/MASLD, BDL, alcoholic liver disease, and others), human liver tissue/single-cell studies, and clinical trials; it also refers to summary Tables 1–7.
  • Main analysis is thematic: it organizes findings by macrophage heterogeneity, mechanistic pathways, therapeutic strategies, risks/context dependence, and translational/clinical evidence.

Limitations

  • The paper explicitly notes that most mechanistic studies rely on in vitro work, frequently using RAW264.7 cells, which “do not faithfully recapitulate” liver macrophages and should be interpreted with caution; this is a stated limitation.
  • It also states that many antifibrotic studies did not systematically assess temporal dynamics or compare effects across distinct hepatic cell populations, limiting mechanistic clarity; this is a stated limitation.
  • Evident from the text: much of the evidence is preclinical and murine, with several clinical interventions showing variable efficacy or limited durability, so direct clinical translation remains uncertain.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fimmu.2026.1792423

Cites

244 of 244 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Liver fibrosis and resolution. Schematic showing main different roles played by macrophages in temporal phases of injury, inflammation and resolution and main signaling events involved.
Figure 1 Liver fibrosis and resolution. Schematic showing main different roles played by macrophages in temporal phases of injury, inflammation and resolution and main signaling events involved.CC BY · PubMed Central
Figure 2 Macrophage-targeted and metabolism driven strategies across the continuum liver fibrosis. (A) This figure illustrates the progression of liver disease from injury to inflammation, fibrogenesis, and ultimately resolution, highlighting a dynamic spectrum of macrophage states from inflammatory to restorative phenotypes. It maps therapeutic strategies onto these phases, showing that early interventions (e.g., CCR2/CCR5 inhibition) target monocyte recruitment, whereas metabolic therapies such as GLP-1 receptor agonists and SGLT2 inhibitors act later to promote fibrosis resolution mainly indirectly. The lower panel integrates key mechanisms—including immunomodulation, metabolic reprogramming, extracellular matrix remodeling, and cell–cell communication—linking therapeutic effects to macrophage-driven regulation of hepatic stellate cells and tissue repair. (B) Graphical summary of antifibrotic therapies in clinical studies. Therapeutic classes are organized along the y-axis, while fibrosis efficacy and macrophage-targeting intensity are represented along the x-axis. Color gradients indicate relative magnitude of effect. Metabolic and combination therapies exhibit the highest antifibrotic efficacy, whereas targeted anti-inflammatory agents show stronger macrophage-directed activity but limited overall fibrosis improvement, highlighting the need for integrated immunometabolic strategies in MASH.
Figure 2 Macrophage-targeted and metabolism driven strategies across the continuum liver fibrosis. (A) This figure illustrates the progression of liver disease from injury to inflammation, fibrogenesis, and ultimately resolution, highlighting a dynamic spectrum of macrophage states from inflammatory to restorative phenotypes. It maps therapeutic strategies onto these phases, showing that early interventions (e.g., CCR2/CCR5 inhibition) target monocyte recruitment, whereas metabolic therapies such as GLP-1 receptor agonists and SGLT2 inhibitors act later to promote fibrosis resolution mainly indirectly. The lower panel integrates key mechanisms—including immunomodulation, metabolic reprogramming, extracellular matrix remodeling, and cell–cell communication—linking therapeutic effects to macrophage-driven regulation of hepatic stellate cells and tissue repair. (B) Graphical summary of antifibrotic therapies in clinical studies. Therapeutic classes are organized along the y-axis, while fibrosis efficacy and macrophage-targeting intensity are represented along the x-axis. Color gradients indicate relative magnitude of effect. Metabolic and combination therapies exhibit the highest antifibrotic efficacy, whereas targeted anti-inflammatory agents show stronger macrophage-directed activity but limited overall fibrosis improvement, highlighting the need for integrated immunometabolic strategies in MASH.CC BY · PubMed Central

Verification

Claims the paper makes

84 Valid · 5 Not valid · 69 Not checked · 45 Own results and interpretations

105 more claims · 34 with their cited sources checked

Create a free account to see all 203 claims and to verify the 16 references still open.

See all claims — free account
  • It may state two separate claims as one. 89
  • Borderline: one of the tests for a substantial claim is unclear. 2
  • Probably not a substantial claim. 3
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Citations

Cites

Show all 243 references

Cited by

See all 1

Metadata

Authors
Aquino, J. B.
Affiliations
Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
Corresponding author
Aquino, Jorge Benjamin
Venue
Frontiers in Immunology
Published
2026-05-12
Volume
17
Pages
1792423-1792423
ISSN
1664-3224 (ISSN-L)
OpenAlex
W7160945889
Cited by
1
References
243
Citations by year
2026: 1
FWCI
0.74
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Consejo Nacional de Investigaciones Científicas y Técnicas (PIP2022)
  • Agencia Nacional de Promoción Científica y Tecnológica (PICT-O-2016-0088)
  • Fondo para la Investigación Científica y Tecnológica (PICT-2017-0642, PIP 2022)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords
liver fibrosis, hepatic macrophages, macrophage reprogramming, fibrosis resolution, antifibrotic therapy, chronic liver disease, immunometabolic reprogramming, NF-κB signaling, PPAR signaling, AMPK, autophagy, mitochondrial function, macrophage heterogeneity, cholestatic liver disease, liver injury, cell therapy, nanotechnology drug delivery
MeSH terms
Metabolic Reprogramming, Animals, Humans, Liver Cirrhosis, Macrophages, Signal Transduction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages. https://app.cochat.ai/papers/10.3389/fimmu.2026.1792423
The paper
Aquino, J. B. (2026). Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1792423

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.